Thalidomide

Various toxicities: case report

A 51-year-old woman received thalidomide at 100 mg/day [*route not stated*] for familial primary cutaneous amyloidosis. She received thalidomide for 12 weeks in total, with a 25mg reduction in dose every 3 weeks. During treatment [*time to reaction onset not clearly stated*] she reported fatigue, drowsiness, numbness of her extremities, and a sense of facial oedema. The symptoms improved as the thalidomide dose was reduced, and laboratory tests were all within normal limits.

An Q, et al. Dramatic improvement of primary cutaneous amyloidosis with thalidomide. European Journal of Dermatology 21: 270-271, No. 2, Mar-Apr 2011. Available from: URL: http://dx.doi.org/10.1684/ejd.2010.1228 - China 803060121